Wednesday, July 8, 2026
🇺🇸 FDA

biotech · Leber Congenital Amaurosis 10 · Sickle Cell Disease · EDIT

Editas Medicine

Editas Medicine patent portfolio — 21 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
Cambridge, USA HQ
2013 Founded
183 Employees
Public company Type
EDIT · NYSE Ticker
Company details
Status
Public
HQ
Cambridge, USA
Founded
2013
Employees
183
Programs
3
Drugs
1
Patents
21
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Patents

Editas Medicine patents

21 pharmaceutical patents indexed for Editas Medicine. 0 expire within 24 months.

Editas Medicine has 21 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

21 patents

Patent portfolio

  1. US 12359223

    Systems and methods for modulating chromosomal rearrangements

    Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12331328

    CRISPR/Cas9-mediated exon-skipping approach for USH2A-associated usher syndrome

    Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12325854

    Crispr-CPF1-related methods, compositions and components for cancer immunotherapy

    Expires Mon Jun 05 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12201699

    Compositions and methods for promoting homology directed repair

    Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12031132

    Systems and methods for the treatment of hemoglobinopathies

    Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11963982

    CRISPR/RNA-guided nuclease systems and methods

    Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11952408

    HPV-specific binding molecules

    Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11911415

    CRISPR/Cas-related methods and compositions for improving transplantation

    Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11851690

    Systems and methods for the treatment of hemoglobinopathies

    Expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11834649

    CRISPR/CAS-related methods and compositions for treating herpes simplex virus

    Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11806408

    Methods and compositions for treating cone-rod retinal dystrophy

    Expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11667911

    Use of exonucleases to improve CRISPR/CAS-mediated genome editing

    Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11597924

    Genome editing systems comprising repair-modulating enzyme molecules and methods of their use

    Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11566263

    Compositions and methods for treating CEP290 associated disease

    Expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11390884

    Optimized CRISPR/cas9 systems and methods for gene editing in stem cells

    Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11390861

    CRISPR/cas-related methods and compositions for treating herpes simplex virus

    Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11242525

    CRISPR/CAS-related methods and compositions for treating sickle cell disease

    Expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11141493

    Compositions and methods for treating CEP290-associated disease

    Expires Mon Oct 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11028388

    CRISPR/Cas-related methods and compositions for treating Usher syndrome and retinitis pigmentosa

    Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11001844

    CRISPR/Cas-related methods and compositions for treating herpes simplex virus

    Expires Mon May 06 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 7788045

    Systems and method for homeostatic blood states

    Expires Mon Aug 26 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Editas Medicine have?

21 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Editas Medicine patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.